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Abstract: Introduction: Type 2 diabetes (T2D) and cardiovascular disease (CVD) risk associate with 
ferritin and percent transferrin saturation (%TS) levels. However, increased risk has been observed at 
levels considered within the “normal range” for these markers.  
Objective: To define normative ferritin and %TS levels associated with T2D and CVD risk.  
Methods: Six-monthly ferritin, %TS and hemoglobin levels from 1,277 iron reduction clinical trial 
participants with CVD (peripheral arterial disease, 37% diabetic) permitted pair-wise analysis using 
Loess Locally Weighted Smoothing plots. Curves showed continuous quantitative ferritin, hemoglobin 
(reflecting physiologic iron requirements), and %TS (reflecting iron transport and sequestration) levels 
over a wide range of values. Inflection points in the curves were compared to ferritin and %TS levels 
indicating increased T2D and CVD risk in epidemiologic and intervention studies.  
Results: Increasing ferritin up to about 80 ng/mL and %TS up to about 25% TS corresponded to in-
creasing hemoglobin levels, and minimal T2D and CVD risk. Displaced Loess trajectories reflected 
lower hemoglobin levels in diabetics compared to non-diabetics. Ferritin levels up to about 100 ng/mL 
paralleled proportionately increasing %TS levels up to about 55%TS corresponding to further limita-
tion of T2D and CVD risk. Ferritin levels over 100 ng/mL did not associate with hemoglobin levels 
and coincided with increased T2D and CVD risk.  
Conclusions: Recognition of modified normal ranges for ferritin from about 15 ng/mL up to about 80-
100 ng/mL and %TS from about 15% up to about 25-55% may improve the value of iron biomarkers 
to assess and possibly lower T2D and CVD risk. 
Keywords: Iron, ferritin, transferrin, diabetes, normal values. 
INTRODUCTION 
Diabetes is associated with bidirectional abnormalities of 
glucose and iron metabolism [1-5]. Meta-analyses of obser-
vational studies have shown that ferritin levels in the general 
population predict type 2 diabetes (T2D) and gestational 
diabetes mellitus (GDM) risk [6-11]. A longitudinal epide-
miologic study showed dose-over-time relationships between 
elevated ferritin levels and increased mortality from diabetes 
and other age-related diseases [12].  Podmore and colleagues 
reported the predictive value of measures of iron status  
for subsequent diabetes risk [13]. These investigators  
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documented continuous linear dose-related associations be-
tween ferritin levels and increased T2D risk in men and 
women with highly significant differences across ferritin 
quintiles. Continuously increasing hazard ratios began at 
ferritin levels above about 100 ng/mL, a level generally con-
sidered to be within the normal range. Quintile boundaries 
placed rising risk in the second quintile for males having low 
and high cut points of 68 ng/mL and 117 ng/mL respec-
tively, and in the fourth risk quintile for women having cut 
points of 73 ng/mL and 121 ng/mL respectively. In contrast, 
reduced T2D risk with higher percent transferrin saturation 
(%TS) levels was observed in women at a cutoff approxi-
mating 45%TS. This association diminished above 50%TS 
and was lost at a cutoff above 55%TS. These findings were 
consistent with progressively reduced capacity for transferrin 
binding of excess iron or redox-active non-transferrin bound 
iron (NTBI) at %TS levels above about 50-55% [13, 14]. A 
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similar trend in men did not reach statistical significance 
possibly due to overall higher ferritin levels in men [14-16].  
We observed that higher ferritin levels correlated with 
mortality during a prospective randomized clinical trial of 
iron reduction in primarily males with cardiovascular disease 
(CVD, peripheral arterial disease, VACSP 410) [17] along 
with increased levels of inflammatory markers: TNF alpha 
(receptor 1), IL6 and hsCRP [18, 19]. Significantly improved 
disease outcomes related to lower ferritin levels [17, 20, 21] 
and with increasing %TS levels in the range of 25-50%TS 
[21]. Mean ferritin levels in participants in CSP 410 at entry 
were about 122 ng/mL and iron reduction targeted ferritin 
levels of 60 ng/mL [17]. Ferritin levels in participants having 
no mortality, or non-fatal myocardial infarction or stroke, 
over 6-years of follow-up averaged 76 ng/mL [17]. In a par-
ticipating institution sub-study, the mean ferritin level corre-
sponding to mortality was 132.5 ng/mL while the mean fer-
ritin in those with no mortality was 82.6 ng/mL [18, 19]. 
These steep dose-effect levels approximated ferritin levels 
associated with reduced morbidity and increased longevity 
observed in other population studies [20, 22-25], as well as 
threshold levels of ferritin and protective %TS levels ob-
served by for T2D risk by Podmore and associates [13].  
These epidemiologic and clinical trial associations sug-
gested revision of normative values for ferritin and %TS 
levels, common measures of iron metabolism, considered 
indicative of the transition from low to increased disease 
risk. Similarities in iron biomarker levels associated with 
T2D risk [13, 15] and adverse vascular disease outcomes 
[17, 21] suggested that examination of graded biomarker 
levels during iron reduction would provide further informa-
tion on quantitative relationships between these biomarkers 
of iron metabolism and disease risk.  
This report demonstrates quantitative relationships be-
tween a wide range of levels of ferritin, %TS and hemoglo-
bin (representing physiologic iron) obtained by direct clini-
cal measurement using Loess plots [26] to display a transi-
tion from physiologic to pathologic markers of iron metabo-
lism predictive of adverse clinical outcomes. We reported 
previously the utility of Loess methodology to characterize 
racial variation in red cell and iron homeostasis [27]. Our 
present findings clarify normative ferritin and %TS levels as 
measures of iron metabolism predictive of lower disease 
risk.   
MATERIALS AND METHODS 
The Iron and Atherosclerosis Study, FeAST, VA Coop-
erative Study Program # 410 (CSP 410); a prospective, 
randomized, controlled single-blinded clinical trial of iron 
reduction; used graded phlebotomy based on ferritin levels 
(Trial Registration: www.clinicaltrials.gov, Identifier 
NCT00032357) [27-29] to test the hypothesis that im-
proved clinical outcomes might be achieved in subjects 
with established CVD by reducing iron stores to levels 
typical of children and pre-menopausal women (about 25 to 
60 ng/mL). The Consort Diagram [28] and methodological 
details of study protocols; informed consent, randomization 
and intervention procedures; outcome assessment and study 
administration have been reported [28-30]. Institutional 
Review Boards (IRBs) at each of the 24 participating hos-
pitals and a national IRB approved the protocol. Consent-
ing (98.8% male) patients over age 21 (average age 67) 
with stable CVD (peripheral arterial disease) were com-
puter randomized by diabetes and smoking status, age, fer-
ritin level, HDL/LDL cholesterol ratio, and medical center 
[28-30]. Thirty-seven percent of the 1,277 subjects had a 
clinical diagnosis of diabetes at entry. This study was de-
signed to optimize opportunity to detect an effect of fol-
low-up ferritin levels on the primary outcome, all-cause 
mortality, and the secondary outcome, death plus non-fatal 
myocardial infarction and stroke. Patients were required to 
have stable CVD for the past 6 months, no disorder of iron 
metabolism including iron deficiency or hemochromatosis, 
no malignancy within the past 5 years, hematocrit of >35%, 
ferritin level of <400 ng/mL, and creatinine <3.0 mg/dL 
[28-30]. Serum ferritin levels up to 400 ng/mL, encoun-
tered commonly in practice [12], were similar for diabetics 
and non-diabetics (see results section). Because diabetes 
was a randomization variable, equivalent numbers of dia-
betics and non-diabetics were randomized to iron reduction 
versus control groups. The use of calibrated phlebotomy 
based on ferritin levels (ml blood to be removed = (ferritin 
level-25) X10) for iron reduction provided a wide range of 
ferritin, %TS and hemoglobin values observed in labora-
tory test panels obtained at 6-monthly intervals during six 
years of observation. Ferritin and %TS levels reported here 
represent the 6-monthly (maximum) levels measured dur-
ing follow-up used to calculate the need for further phle-
botomy. For purposes of this report, quantitative data at 
entry were examined for normality using the Shapiro-Wilk 
test [31] and found to be not normally distributed. Thus, 
quantitative data are presented below as medians with 25th 
and 75th percentiles. Statistical significance between 
groups was tested using the Wilcoxon test [32]. 
Loess Locally Weighted Scatter Smoothing Plot analysis 
[26] was used to detect interrelationships between these vari-
ables. This method permits construction of a smooth curve in 
order to visualize relationships between two variables over a 
continuum not otherwise recognizable within large popula-
tions [33-35]. Inflection point relationships between two 
variables of interest allow identification of subpopulations 
within a larger clinical trial population with unique charac-
teristics associated with graded risk of adverse clinical out-
comes [36, 37]. Measures of interest included relationships 
between ferritin, %TS reflecting iron transport and seques-
tration, and hemoglobin levels reflecting physiologic iron 
status. Loess methodology has been used to show relation-
ships between individual laboratory variables and clinical 
outcomes in studies of diabetes [36-39] and CVD [27, 40, 
41]. The present study plotted relationships between ferritin 
and hemoglobin levels (8388 paired samples, Fig. 1), be-
tween %TS and hemoglobin levels (8371 paired samples, 
Fig. 2) and between ferritin and %TS levels (8371 paired 
samples, Fig. 3). Loess curves were examined for inflections 
below or above which adverse clinical events were less or 
more likely to occur. Relevance of observed inflection points 
to clinical outcomes was based on outcomes from clinical 
trial findings [17, 21, 28] as well as epidemiologic studies 
assessing iron biomarker levels and risk of T2D and CVD 
[12, 13, 16]. 
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Fig. (1). Loess smoothing plots of 8388 paired values of hemoglo-
bin and ferritin in diabetic and non-diabetic participants during the 
iron reduction trial, CSP 410. The range of values is depicted in the 
axes of the figure. Vertical arrows approximate inflection points 
associated with the limits of hemoglobin iron requirement, and 




Fig. (2). Loess plots of 8371 paired values of hemoglobin and %TS 
in diabetic and non-diabetic participants during the iron reduction 
trial, CSP 410. The range of values is depicted in the axes of the 
figure. The vertical arrow shown here at about 20%TS approxi-
mates the inflection point (of 20-25%TS) representing transport 





The FeAST study included 1,277 entrants, 473 of whom 
were diabetic and 804 non-diabetic at entry. Levels of fer-
ritin, %TS and hemoglobin found at entry are expressed here 
as medians with 25th and 75th percentiles in parentheses. Me-
dian levels of ferritin of 103 ng/mL (61 ng/mL, 170 ng/mL) 
and 103 (58, 168) ng/mL, (p=0.681); and median levels of 
%TS were 23.4% (18.7%, 30.1%) and 24.7% (18.8%, 
30.8%), (p=0.141) were similar at entry for diabetics and 
non-diabetics respectively. Median entry levels of hemoglo-
bin were slightly but statistically significantly lower in dia-
betics compared to non-diabetics: 14.5 g/dL (13.5 g/dL, 15.3 
g/dL) versus 14.8 g/dL (13.9 g/dL, 15.7 g/dL), (p<0.001). 
Loess plot trajectories for diabetic and non-diabetic partici-
pants were similar but displaced for diabetics as shown in 
figures 1 and 2 owing to lower hemoglobin levels in diabet-
ics.  
Fig. (1) shows Loess smoothing plots for hemoglobin and 
ferritin paired values. Levels of both increase in parallel up 
to an inflection point at ferritin levels approximating 80-100 
ng/mL reflecting a possible mean upper limit for the physi-
ologic “normal range” (represented by hemoglobin levels) 
for both measures. Loess curves for diabetics and non-
diabetics were roughly parallel but displaced downward in 
diabetics as predicted by the significantly lower hemoglobin 
levels in diabetic participants. The inflection point for the 
hemoglobin level may be interpreted as occurring at a 
somewhat lower ferritin level in diabetics compared to non-
diabetics. However, ferritin levels below about 80-100 
ng/mL followed a similar trajectory in diabetics and non-
 
Fig. (3). Loess plots of 8371 paired ferritin and %TS values in dia-
betic and non-diabetic participants during the iron reduction trial, 
CSP 410.  The range of values is depicted in the axes of the figure. 
Rising curves overlap with an inflection point marked by the left-
hand vertical arrow at about 25%TS and about 80 ng/mL ferritin 
(similar to values shown in figures 1 and 2). The right-hand vertical 
arrow marks a second inflection point at about 55%TS and 100 
ng/mL of ferritin.  
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diabetics. Ferritin levels above the transition at about 80-100 
ng/mL lacked physiologic correspondence to increasing he-
moglobin levels, an effect that was exaggerated in diabetics 
and possibly contributory to “anemia” in certain diabetics 
[42].  
Fig. (2) shows the Loess plots of paired hemoglobin and 
%TS levels. As in Fig. (1), these plots also were roughly 
parallel but displaced downward in diabetics. The inflection 
point for hemoglobin levels depicted in Fig. (2) occurred at 
about 20%TS in both diabetics and non-diabetics. Levels 
plateaued above about 25%TS and followed roughly similar 
trajectories in relation to hemoglobin levels in diabetics and 
non-diabetics throughout the range of values in this data set.  
Fig. (3) shows Loess plots of paired ferritin and %TS 
levels which increase synchronously with overlapping curves 
in diabetics and non-diabetics up to levels of about 55%TS. 
The plateau above about 25%TS, the presumed cutoff for 
physiologic levels of transport iron for erythropoiesis repre-
sented by the %TS level, is similar to that in Fig. (2). Curves 
flatten but continue to overlap as levels of both rise in pro-
portion to each other for ferritin levels up to about 100 
ng/mL and %TS levels up to about 55%TS. However, curves 
for diabetics versus non-diabetics diverge at ferritin levels 
above about 100 ng/mL and %TS levels above about 55%. 
Above these levels, dissociation of these measures appeared 
in which a further increase in ferritin levels is accompanied 
by a proportionate rise in %TS in non-diabetics while a less 
proportionate ferritin/%TS response occurred in diabetics.  
DISCUSSION 
Loess plots for diabetic and non-diabetic cohorts differed 
because of slightly lower hemoglobin values in diabetics 
related presumably to “anemia of chronic disease” occurring 
in some diabetics [42]. However, inflection points in relation 
to hemoglobin levels occurred in both diabetic and non-
diabetic cohorts for ferritin levels at about 80-100 ng/mL, 
and for %TS levels at about 25% TS (Figs. 1 and 2, respec-
tively). Increasing ferritin levels up to these inflection points 
suggest increasing physiologic incorporation of iron into 
hemoglobin. 
Data presented in Fig. (1) suggest that ferritin levels ap-
proximating 80-100 ng/mL represent an upper normal limit 
of physiologic levels of body iron as related to correspond-
ing hemoglobin levels. Ferritin levels over the 80-100 ng/mL 
range appear to lack physiologic correspondence with hemo-
globin levels. Thus, normative values for the serum ferritin 
may range from the commonly accepted lower limit of less 
than about 15 ng/mL to an upper limit of about 80-100 
ng/mL as observed in this study. This threshold ferritin level 
coincides with levels associated with increased T2D risk 
observed epidemiologically [13] as well as adverse outcomes 
observed in clinical trial data [17, 21].  
Fig. (2) shows proportionately increasing hemoglobin 
and %TS levels up to about 20-25%TS. Rising %TS levels 
gradually plateau above an inflection point of about 25% in 
relation to corresponding hemoglobin levels. Transferrin 
saturation levels below about 20-25% may be consistent with 
transport of iron as holotransferrin for erythropoiesis [14]. 
Levels above about 25%TS imply a possible switch to incor-
poration of iron in physiologic excess (or possibly redox-
active NTBI) onto transferrin [14].  
The proportionate increase in ferritin and %TS values 
shown in Figure 3 up to ferritin levels of about 80 ng/mL and 
%TS levels of about 25% suggests strict physiologic corre-
spondence or compensation of these functionally different 
proteins representing balance between ferritin and transferrin 
as they interact to maintain optimal (compensated) iron ho-
meostasis [14] associated with minimal disease risk [13, 17, 
21]. The curves flatten above ferritin levels of about 80 
ng/mL and %TS levels above about 25% but then increase 
proportionately up to about 100 ng/mL of ferritin of and 
about 50-55%TS. These relationships suggest sustained 
compensation by an increase in %TS as related to increasing 
ferritin levels. Podmore and colleagues [13] also observed 
apparent clinical compensation for increasing ferritin levels 
with increasing %TS levels up to about 50-55%TS which 
appeared to protect against T2D risk. The transition from 
physiologic to apparently de-compensated (disproportion-
ately increasing) levels above about 50-55%TS in women 
was associated with increased T2D risk in that study [13]. 
We also noted a similar inflection point in our male partici-
pants with CVD at about 25%TS (Figs. 2 and 3). The present 
data suggest a transition from presumably protective to po-
tentially toxic %TS levels above a range of about 25-55%TS 
in males (Figs. 2 and 3). Progressive iron loading may ex-
ceed the capacity for physiologic compensation by transfer-
rin that may be most efficient when ferritin levels remain 
below about 80-100 ng/mL [17, 21]. Iron biomarker relation-
ships shown in Figures 2 and 3 corresponding closely to the 
epidemiologic findings of Podmore and colleagues [13] for 
their observed hazard ratios for ferritin and %TS for T2D 
risk. The apparent functional dissociation of ferritin and 
%TS above these levels suggests a testable hypothesis that 
transferrin may become occupied increasingly with poten-
tially toxic NTBI at ferritin levels considered previously to 
be normal [14, 43-45]. 
Differing functions and regulatory control of ferritin as 
compared to %TS levels may also explain the positive 
association of ferritin levels with the inflammatory markers, 
TNF alpha, IL6 and hsCRP, [18, 19, 43] as well as the 
negative association of these inflammatory markers with 
%TS levels [42]. In accord with these findings, Podmore and 
colleagues also recorded that lower ferritin levels and higher 
%TS associate with lower hsCRP levels [13]. Side-by-side 
comparison of quantitative %TS data reported here coincides 
with clinical outcome data reported in epidemiologic [13] 
and clinical trial outcome [21] data. Protective effects appear 
to exist for %TS levels up to about 50-55% both diabetes 
risk [13] and CVD outcomes [21].       
REVISED NORMAL RANGES FOR IRON STATUS 
AND LONGEVITY 
The revised normal ranges for these biomarkers of iron 
metabolism suggested here bear striking resemblance to 
other estimates of disease risk in relation to increasing fer-
ritin and %TS levels. Population mean ferritin levels vary 
considerably by age, race and sex while %TS levels appear 
to be relatively stable [20, 21, 27]. Mean ferritin levels up to 
approximately 60-70 ng/mL in the late teens in males and 
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females associate with low disease risk [17, 23-25]. Popula-
tion levels in males increase at a rate of about 4 to 5 ng/mL 
per year and plateau at a mean of about 140-150 ng/mL as-
sociated with increasing disease risk by middle-age [20]. 
Cross-sectional measures of ferritin decline gradually with 
increasing age to range at about 80-100 ng/mL suggesting 
that such lower levels select for greater longevity [20, 24, 
25] as illustrated in CSP 410 outcomes data [17]. Low risk 
mean ferritin levels below about 50 ng/mL in pre-
menopausal women rise after menopause to plateau at ap-
proximately 80-100 ng/mL about 30 years earlier in women 
compared to men [20]. The increase in ferritin levels above 
this threshold associate with increased post-menopausal dis-
ease risk in women [46]. Occurrence of ferritin levels in this 
range at an earlier age in women correspond to their in-
creased risk for T2D above this threshold [13]. Higher fer-
ritin levels relate to increasingly impaired beta cell function, 
insulin resistance and metabolic abnormalities characterizing 
diabetes [5, 47, 48].  
Ferritin levels below about 80-100 ng/mL relate to mini-
mal disease and maximum longevity observed in other stud-
ies [17, 20, 22-25]. Individuals in the elderly Framingham 
Heart Study cohort having a mean age of 75 (age range 68-
93) but lacking a clinical disease diagnosis had mean ferritin 
levels of 86 ng/mL whereas members of the same elderly 
cohort having a clinical disease diagnosis had a slightly 
higher mean ferritin level of 94 ng/mL [22].  Percent TS lev-
els in the Framingham Heart Study cohort were lower in 
individuals without a clinical diagnosis, 25%TS, compared 
to individuals having a clinical disease diagnosis, 35%TS. 
Based on data shown in Figure 3, 25%TS would be consid-
ered within the low risk range and 35%TS, while higher, 
would remain in the compensated range. Data from a cohort 
of males from the Mediterranean region of Europe over age 
80 having relatively low morbidity and mortality had mean 
ferritin levels of 68 ng/mL [23]. These levels were signifi-
cantly lower than levels found in a male population of simi-
lar age from The Netherlands having significantly greater 
morbidity associated with mean ferritin levels of 137 ng/mL. 
Adjusted mean %TS levels were 20% in the healthier Medi-
terranean population versus 34% in the sicker Northern 
European population. Based on our findings, the healthier 
Mediterranean population having mean %TS levels of 20% 
would be within the low risk range while the higher risk 
Northern Europeans of the same age having mean %TS lev-
els of 35%, while slightly higher, would remain in the com-
pensated range. Residents of the Mediterranean region are 
known to have a lower risk of T2D [49], vascular disease 
and malignancy [23]. These estimates resemble NHANES III 
data showing a similar pattern for ferritin levels in free-
living older age individuals [20]. 
REVISED NORMAL RANGES FOR IRON MEAS-
URES AND DIABETES RISK  
The validity of the revised normal values for measures of 
iron status reported here is supported by several studies of 
T2D risk. A prospective randomized interventional trial in 
T2D examined effects of rigorous dietary iron restriction 
(total n = 191, evaluable n = 170) on development of end 
stage renal disease requiring transplantation or all-cause 
mortality over a mean follow-up of about 4 years [50]. The 
mean ferritin level for the total cohort at entry was 301 
ng/mL. Levels remained unchanged during follow-up in con-
trol subjects but declined to a mean of 36 ng/mL (p<0.001) 
in subjects randomized to dietary iron restriction. Iron reduc-
tion was associated with a significant reduction in the pri-
mary study endpoint, p<0.01, and significantly reduced risk 
of doubling of the serum creatinine, p<0.02.  
Ogawa, et al [25] reported clinical outcome data from a 
cohort of patients on chronic hemodialysis, 21% of whom 
had diabetic nephropathy. Ferritin levels between about 30 
ng/mL and 80 ng/mL were associated with significantly im-
proved long-term survival (p=0.013) compared to survival 
with higher or lower ferritin levels and hemoglobin status.  
Strong continuous statistical associations exist between 
ferritin levels and insulin resistance (IR) measured typically 
by the Homeostasis Model Assessment of Insulin Resistance 
(HOMA-IR) assay [51-54]. Correlations between IR and 
ferritin levels above about 99 ng/mL in men and above about 
86 ng/mL in women have been reported [50]. Kim et al [54] 
showed significant positive statistical associations between 
levels of insulin, fasting glucose and HOMA-IR with ferritin 
levels above 98 ng/mL in post-menopausal women (p<0.001 
for each comparison). Relationships between iron measures 
and HOMA-IR were tracked longitudinally in a cohort of 
otherwise healthy non-diabetic women followed from pre-
menopause to one-year post-menopause [55]. During meno-
pausal transition, fasting glucose (p=0.05) ferritin (p<0.01) 
and HOMA-IR (p=0.022) increased significantly. Mean pre-
menopausal ferritin levels were 69.5 ng/mL and mean post-
menopausal ferritin levels 128.8 ng/mL, resembling low ver-
sus increased risk levels observed in the present and other 
studies [20,22,23]. Improved IR with removal of a single 
unit of blood (500 mL, estimated to reduce ferritin levels by 
about 50 ng/mL in a healthy individual) reinforces the con-
cept that IR risk may be a continuum related to the ferritin 
level [56].  
Relationships between iron measures and T2D risk 
[57,58] are relevant to vulnerable populations predisposed 
metabolically to diabetes associated with overall increased 
ferritin levels [21,27,58-60]. Living at high altitude corre-
lates with both reduced diabetes risk [61] along with lower 
ferritin levels [62]. Treatment of diabetes with the oral hypo-
glycemic agent, metformin, significantly reduces risk of dia-
betic co-morbidities [63-70]. The anti-diabetic properties of 
metformin may be linked to the metal binding properties of 
this drug [71]. A 3-month course of metformin reduced fer-
ritin levels by about 50% (p<0.001) and improved insulin 
resistance in a cohort of women with polycystic ovary syn-
drome [72].  
LIMITATIONS OF THIS STUDY  
CSP 410 focused on clarification of the role of iron ex-
cess in the pathogenesis of CVD that may be potentially 
linked to multiple factors that were not investigated in this 
clinical trial. Free-living CVD patients with and without dia-
betes likely have various co-morbidities or more advanced 
disease associated with higher ferritin levels than are repre-
sented in this cohort [73]. Elevated ferritin levels may relate 
to increase in iron stores, inflammatory response, or a com-
bination of both. The plots obtained from the present partici-
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pants may not be characteristic of the general population.  
Loess curves reported here were derived from a population 
consisting almost entirely of males. Curves derived from a 
population of females may also differ from those obtained in 
CSP 410. Measures of hepcidin, NTBI [74-76], glycated 
hemoglobin, insulin resistance, inflammation and possibly 
other variables were not available in this study. T2D risk 
may also be attributable to socio-economic factors, environ-
mental contaminants [77-79] or Western Lifestyles [80]. 
These require further investigation of their effects on iron 
biomarkers and associated iron metabolism.  
STRENGTHS OF THIS STUDY 
Ferritin levels at entry to CSP 410 were a randomization 
variable considered a “signal” of iron metabolism conveying 
prognostic information. Ferritin levels at entry and intent-to-
treat ferritin levels during follow-up were interpreted at face 
value to determine the amount of blood to be withdrawn by 
phlebotomy without attempting to differentiate between 
acute phase and non-acute phase levels. Strengths that render 
data on iron biomarkers suitable for the present analysis in-
clude study’s prospective, randomized single-blinded design, 
and longitudinal analysis of a wide range of levels of the 
variables of interest. Iron reduction was based on levels of 
the primary variable of interest (the serum ferritin level) as 
modified with randomization to calibrated phlebotomy [17, 
21]. Ferritin levels in this study are observed commonly in 
the general population and were subject to experimental 
variation [17] as well as natural variation in free-living popu-
lations [17, 20]. Diabetes status was also a randomization 
variable; similar numbers of diabetics and non-diabetics 
were randomized to iron reduction as compared to control 
[27-30]. Ferritin and %TS levels reported here were similar 
between diabetic and non-diabetic entrants while hemoglo-
bin levels were significantly lower in diabetics. Loess meth-
odology identified break points in a continuum of ferritin 
and %TS levels that corresponded to clinical risk [13, 17, 
21]. Cut points in Loess curves may reflect an apparent tran-
sition from physiologic to pathologic iron biomarker levels 
that appeared to be similar between participants with or 
without T2D. Thus, the demonstrated quantitative relation-
ships for ferritin and %TS levels that distinguish physiologic 
from non-physiologic ferritin levels of these biomarkers or 
iron metabolism may facilitate clinical correlation of obser-
vations on iron-mediated pathways and risk of T2D [81-83], 
its complications [84-86] and its co-morbidities [87-90]. Iron 
biomarker values reported here might be extrapolated to co-
morbidities of diabetes besides CVD. For example, malig-
nancy may have a similar hypothetical pathophysiologic 
narrative, i.e., damage to cells and tissues caused by iron-
catalyzed oxygen free radical generation [24, 91]. CSP 410 
data reported previously showed reduced risk of new visceral 
malignancy (p=0.036), and all-cause and cancer-specific 
mortality (p=0.009) with randomization to iron reduction 
[92]. Mean follow-up ferritin levels in entrants not develop-
ing cancer as compared to those developing cancer were 76.4 
ng/mL versus 127.1 ng/mL respectively (p=0.017). These 
ferritin levels also correspond to lower versus higher risk 
values as suggested by the present report. Additionally, fer-
ritin levels below about 100 ng/mL are recommended for 
optimal management of diseases of iron excess by the 
American Association for the Study of Liver Disease [92].  
CONCLUSION 
The wide range of putatively “normal” serum ferritin 
levels, 30-300 ng/mL in men and 15-200 ng/mL in women, a 
10-fold variation, represent extreme variations that do not 
resemble the range of normal values for other laboratory 
metabolic measures [2, 24]. Revised normal values as re-
flected by relationships between ferritin, %TS and hemoglo-
bin observed in the present study also associate with epide-
miologic and clinical trial data predicting favorable clinical 
outcomes. Optimal (minimum risk) serum ferritin levels ap-
pear to range from a low of about 15 ng/ml to about 80-100 
ng at an upper limit. Data analyzed here for %TS levels re-
semble the range of normal as accepted commonly having a 
lower limit below about 15% and an upper limit of about 
55%. We suggest that %TS levels up to about 25% may re-
flect iron transport for erythropoiesis. Ferritin in relation to 
%TS levels ranging between about 25% and 55% may re-
flect compensation by transferrin scavenging of iron or 
NTBI up to ferritin levels of about 100 ng/mL. Ferritin and 
%TS levels within these ranges appear to associate with 
lower T2D [13] and CVD risk [21].  
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